Actively Recruiting
Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics
Led by Nantes University Hospital · Updated on 2026-04-03
1401
Participants Needed
6
Research Sites
167 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Severe bacterial infections (SBI) are responsible for significant morbidity and mortality in the paediatric population. There is considerable individual variability in children's susceptibility to developing SBIs. This variability is multifactorial, and the mechanisms at work are not yet fully understood. The investigators of this study therefore propose to study a population of children who had particularly severe bacterial infections requiring hospitalization in a pediatric intensive care unit in France between 2015 and 2018. This study is part of a global approach to understanding the mechanisms favoring the occurrence of IBS in pediatrics. The study will initially focus on analyzing the clinical phenotype of these children in terms of the type of infection presented, as well as immunologically with an immune workup of all these patients. The investigators also plan to contact each family individually to identify other episodes of personal or family IBS or other elements suggestive of immune deficiency (opportunistic infections, autoimmune manifestations, severe atopy). The investigators will also assess the persistent sequelae since their infectious episode, and their quality of life following this IBS. In parallel, the genetic analysis of these patients and their parents will be carried out using whole-exome sequencing. The investigators will compare the results with those obtained in 2 IBS-free control populations (N=70 and N=116). The goal is to identify genetic variants that favor the occurrence of IBS in general, and some that are specific to certain bacteria or clinical presentations.
CONDITIONS
Official Title
Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient included in the DIABACT IV study between 2015 and 2018, following hospitalization in a pediatric intensive care unit in France for a severe bacterial infection.
- Patient affiliated to a social security system
- Patient alive at the time of inclusion.
- Written consent from legal representatives for participation in research. If one of the legal representatives is unable to complete/sign the written consent, it will be sought orally by telephone and recorded in the patient's file. If the patient is over 18, written consent will be obtained. If the patient is a minor, consent will be sought with communication adapted to his/her level of understanding and age.
- Patient's biological parents
- Written consent
You will not qualify if you...
- Persons under court protection
- Refusal to participate in research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Nantes University Hospital
Nantes, Loire Atlantique, France, 44093
Actively Recruiting
2
CHU de Brest
Brest, France
Not Yet Recruiting
3
Hospices Civils de Lyon
Lyon, France
Not Yet Recruiting
4
Hôpital Armand Trousseau
Paris, France
Not Yet Recruiting
5
Hôpital Necker enfants malades
Paris, France
Not Yet Recruiting
6
CHU de Saint-Étienne
Saint-Etienne, France
Not Yet Recruiting
Research Team
E
Elise LAUNAY
CONTACT
S
Sponsor Department
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here